

Formulary Update

August 2025

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since June 2025. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Dydrogesterone	Female hormone treatment	6.4.1.2	No licensed non-combination formulations available
Insulin glargine/lixisenatide	diabetes	6.1.2.3	No licensed products available
Kaolin Poultice	Topical pain relief	10.3.2	On Scottish Government low clinical value medication list
Minocycline	acne	13.6.2	On Scottish Government low clinical value medication list
Nandrolone	Steroid treatment	6.4.3	No licensed products available
Neofordex	Corticosteroid treatment	6.3.2	No licensed products available
Parathyroid hormone	Thyroid disease	6.6.1	No licensed products available
Saxagliptin/metformin	Diabetes	6.1.2.7	No licensed products available
Additions	Indication	Adult Medicines Formulary entry/ rationale	
Thiamine IM injection	Alcohol detoxification	9.6.2	Formulary change request
Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Denosumab	Brand name removed	6.6.2	Now available as biosimilar
Nitrofurantoin	Prescribing note added 'Please note nitrofurantoin is NOT effective in upper urinary tract infections as it does not achieve effective concentrations in the blood'	5.1.13	On request of antimicrobial team

PDE5-inhibitors	Restriction changes allowing generic sildenafil to be prescribed without restrictions but other medicines in class to retain SLS endorsement requirements	7.4.5	National change to restrictions
Rezafungin	Prescribing restriction reworded to clarify it is restricted to be used via OPAT service to facilitate discharge.	5.2.4	Request by antimicrobial team
Sofosbuvir/ velpatesvir	Brand name Epclusa removed	5.3.3	Product has been debranded
ticagrelor	Brand name Brilique removed as now available generically	2.9	National Procurement advice
Chapter 8 housekeeping	Brand names removed for: azacitidine (injection), bosutinib, cabozantinib, sorafenib, trabectedin, fulvestrant, degarelix.	8	Now available as generics
Chapter 6 housekeeping	Oestrogens and HRT: Restructured subchapter to divide into oestrogen-only and combination products (the latter of which are then sub-divided into sequential combined therapy and continuous combined therapy).	6.4.1.1	Improved user interface